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Cyclosporin A (CyA) has recently been shown to be
effective in frequently relapsing, steroid-resistant or
steroid-dependent childhood nephrotic syndrome (NS).
Wider acceptance has been hindered by considerations of
cost, toxicity and drug-dependent maintenance of
remission. Black children in Africa with NS are mainly
steroid-unresponsive and alternative therapies therefore
need to be assessed.
We report on 8 of 11 children who completed at least 24
weeks of CyA therapy; 6 (2 with membranous nephropathy
(MEM) and 4 with focal glomerulosclerosis) showed no
improvement, while 2, both with MEM, achieved remission
while on CyA therapy and remained in remission for 1 and
3,5 years, respectively, after cessation of therapy. This
may have been the natural course of the disease. Of the
children who were unresponsive to CyA, 3 died in renal
failure 8 - 30 months after cessation of CyA therapy, 1 had
a rising creatinine value when last seen, and 2 were lost
to follow-up. CyA trough levels varied between 180 and
875 ng/ml and peak levels between 563 and 1 950 ng/ml.
Of 5 repeat renal biopsies, 3 were performed at the end of
24 weeks of treatment and revealed no evidence of CyA
toxicity. Two biopsies revealed chronic CyA toxicity. CyA
should therefore be used with caution at lower dosages
and monitored at currently accepted lower trough levels in
children with NS in Africa.
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Cyclosporin A (CyA) is the mainstay of immunosuppressive
therapy in all transplant centres and has been used more
recently in auto-immune disease'.2 and in nephrotic
syndrome (NS). It has been shown to be useful in steroid-
resistant, steroid-dependent" and steroid-responsive
frequently relapsing NS, and in patients with steroid toxicity.·
Major disadvantages of CyA are nephrotoxiCity and relapse
on cessation of therapy! There is no suitable or effective
therapy for the black child with NS in South Africa, because
these patients are usually steroid-insensitive.5,6 Among Indian
South Africans the pattern of NS is similar to that in white
children and focal glomerulosclerosis (FGS) therefore poses
a major therapeutic challenge.
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In contrast to the present situation, when we first
considered the use of CyA for NS in 1984, little information
was available on the use of this drug in children, particularly
in blacks. Accordingly, a study was embarked upon to
determine suitable dosages, duration of therapy, toxic
effects and the likely therapeutic advantages of CyA in
nephrotic children who were steroid-resistant or for whom




Selection criteria for entry to the study included oedema,
hypo-albuminaemia « 30 g/l), massive proteinuria (> 2
g/rri/d) , any black or Indian child with FGS, and
membranous nephropathy (MEM), or minimal change
disease (MCD) in blacks. Criteria for exclusion were acute or
chronic viral, fungal or bacterial (including tuberculosis)
infections, impaired hepatic, renal or neurological function,
concomitant therapy with nephrotoxic agents, cytostatics,
ketoconazole, phenytoin, barbiturates, rifampicin, isoniazid
or steroids, malabsorption, cancer, end-stage irreversible
renal disease, diabetes mellitus, uncontrolled hypertension
and drug or alcohol abuse.
Clinical evaluation
During the trial patients were evaluated clinically for signs
and symptoms of NS and for side-effects of CyA. They were
monitored for hepatic dysfunction (serum bilirubin value
> 17 mmol/l, 3-fold increase in aspartate aminotransferase
(AS1)), renal dysfunction (serum creatinine value> 160 ~mol,
hypertension), neurological dysfunction (tremor,
hyperparaesthesiae, convulsions), and general effects such
as hirsutism and gum hypertrophy.
Laboratory investigations
Laboratory investigations included a full blood count and
measurement of blood urea, electrolytes and creatinine
values, serum albumin, globuliri, calcium, phosphorus,
bilirubin, alkaline phosphatase, AST and gamma-glutamyl
transpeptidase; the urine was tested for blood, bilirubin,
urobilin and glucose. Clinical evaluation and laboratory
investigations were performed just before commencing CyA
therapy, weekly for 4 weeks, every 2 weeks for 16 weeks,
then every 4 weeks until 32 weeks. T-Iymphocyte
subpopulations were determined using the OKt series of
murine monoclonal antibodies (Ortho Pharmaceuticals
Corporation, Raritan, NJ). These data have been reported'
and are therefore not included in this study. These tests
were undertaken before commencement of CyA therapy and
24 weeks later.
Cyclosporin dosage
In order to establish the dosage of CyA to achieve adequate
whole-blood trough levels, CyA was commenced at 2,5
mg/kg/d in 2 divided doses and increased to achieve to
trough levels of 250 - 1 000 ng/ml. CyA was measured by
radio-immunoassay.6 The course was given for 24 weeks.
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Patients were withdrawn from the study if non-compliant or
if any of the signs of toxicity occurred. Renal biopsy was
repeated, if possible, after 24 weeks of therapy.
Patient details
On the basis of the above criteria 11 patients with NS (10
black and 1 Indian) were studied; their ages ranged from 2
to 14 years, and 5 were males. The duration of NS before
commencing CyA therapy ranged from 6 to 39 months.
Histological findings at the start of the project indicated that
5 patients had hepatitis B surface antigen (HBsAg)-
associated MEM, 3 FGS (1 Indian), 2 MCD and 1
proliferative nephropathy. One of the 2 black children
classified as having FGS had evidence of MCD on the first
biopsy but was found to have FGS on repeat biopsy 13
months after cyclosporin therapy (referred to as MCD/FGS).
All the children were given diuretics and a salt-restricted
diet. Three of the black patients (2 MCD, 1 FGS) were given
steroids without response. The Indian child with FGS was
given both steroids and cyclophosphamide, with little effect.
Results
Clinical course and outcome (Table I)
Eight of the 11 patients completed at least 24 weeks of CyA
therapy; 4 of these 8 continued to 28, 32, 32 and 36 weeks,
respectively. Of the 3 children who did not complete 24
weeks of treatment, 1 with MEM developed massive
haematuria at 6 weeks and careful investigation ascribed the
cause of the haematuria to cystitis unrelated to CyA. A
patient with proliferative nephropathy was withdrawn by the
parents at 7 weeks, and another with MCD defaulted after
completing 12 weeks of treatment.
Table I. Cyclosporin treatment - patient details
Trough
Age levefs
Patient (yrs) Sex Histology (ng/ml) Outcome
7 F MEM* 210 - 250 Remission
2 6 M MEM* 170 - 300 Remission
3 7 M MEM 320 - 350 No change
4 11 M MEM 220 - 390 No change
5 9 F FGS* 270 - 330 No change




7 14 M FGS 450 - 875 No change.
Death 10 moo
after CyA





'No acute CyA toxicity after 24 wks of CyA.
ESK = end-stage kidney 10 moo after CyA; CT = chronic CyA toxicity.
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At the end of their course of treatment 6 patients (2 MEM,
3 FGS, 1 MCD/FGS) showed no change in their NS. Two
patients, both with MEM, achieved remission while on CyA;
in 1·ofthese patients the HBsAg and hepatitis B e antigen
cleared progressively during the course of therapy. The
serum creatinine levels in these 2 patients remained normal
throughout the course of therapy and they continued in
remission for 1 and 3,5 years, respectively, after cessation of
CyA therapy.
The subsequent course in 3 of the 6 patients whose NS
was unresponsive to CyA is as follows. The patient with FGS
died 2,5 years after cessation of CyA therapy; she had not
attended follow-up visits for 2 years because of fami~y.­
difficulties. The baseline serum creatinine value was 35
mmol/I and 4 months after withdrawal of CyA it was 60
mmol/l. She was admitted in renal failure, with a blood
pressure of 144/100 mmHg, a haemoglobin concentration of
6 g/dl, a blood urea value of 54 mmol/l, and a serum
creatinine value of 1 128 mmol/l. Despite dialysis and
transfusion she died 24 hours after admission. The child
with MCD/FGS, who had had CyA for 32 weeks, p~esented
8 months later unable to walk and with painful knees.
Rickets was diagnosed. At this time investigations revealed
the follOWing: blood urea 12,6 mmol/I, serum creatinine
106 mmol/l, serum calcium 1,5 mmol/I, serum phosphate
0,75 mmol/l, alkaline phosphatase 1 329 U/I, phosphate
excretion index 0,22% (normal-D,09 - +0,09%), and
25-hydroxyvitamin D 5 ng/ml « 10 ng/ml indicates vitamin D
deficiency). She had metabolic acidosis and panamino-
aciduria. It was believed that she had developed vitamin D
deficiency together with a Fanconi-like syndrome. Four
months after having been given oral calcium, phosphate,
1-a-vitamin D and a solution of sodium citrate and citric
acid in adequate doses to achieve normal levels of calcium,
phosphorus and alkaline phosphatase, she showed no
clinical improvement and in addition suffered a crack
fracture of the lower left femur. When last assessed her
creatinine level was steadily rising. The remaining child, an
Indian boy with FGS, had a severe relapse and died in renal
failure 10 months after cessation of CyA therapy; while on
CyA he did not improve, and his clinical condition fluctuated
as it had before treatment with the drug was started. His
creatinine value rose gradually, even after cessation of
therapy.
Of the remaining 3 children who did not respond to CyA,
1 had a rising creatinine level (above 80 mmol/l) when last
examined, and 2 have not attended for follow-up.
CyA dosage and-blood levels
Adequate drug levels (trough 250 - 1 000 ng/ml) were
achieved in 8 patients at a dosage of 10 - 15 mg/d and in
2 at 7,5 mg/d by 4 - 12 weeks. The patient who was
withdrawn by his parent had not attained adequate levels.
The 2 patients with MEM who achieved remission on CyA
did so at trough levels of 210 - 250 ng/ml and 170 - 300
ng/ml, respectively. The black child with FGS who died 2,5
years after stopping CyA therapy had trough levels of 180 -
280 ng/ml, and peaks of 563 - 1 150 ng/ml. The patient witb
rickets and chronic renal insufficiency had trough levels of
240 - 280 ng/ml, but peak levels of 1 250 - 1 550 ng/ml.
The Indian boy with FGS who died had trough levels of 450
- 875 ng/ml, and peaks of 875 - 1 950 ng/ml.
Toxic effects of cyclosporin during the
treatment period
Except for hypertrichosis in 1 patient, other features such as
gum hypertrophy, hirsutism and neurological side-effects
(tremors, paraesthesiae and convulsions) were not seen in
any of the patients. Hepatic dysfunction (according to the
definition of a bilirubin level exceeding 17 mmol/I or a 3-fold
increase in ASl) did not occur, but the serum bilirubin value
had increased 2 - 3-fold from baseline levels in 5 of the 9
patients. Similarly, creatinine levels rose 2 - 4 times above
baseline values in 5 patients, but did not exceed 160 IJmol/1.
For the occurrence of nephrotoxicity see below.
Renal biopsies
Five repeat biopsies were available. Three patients had
repeat renal biopsies at the end of their 24 weeks of
therapy; none showed' any histological evidence of acute
CyA toxicity (these have been reported on previously'). The
patient with chronic renal failure and rickets underwent a
repeat biopsy 13 months after cessation of CyA therapy.
Eleven glomeruli were present. The interstitium showed
severe fibrosis with associated tubular atrophy. The fibrosis
alternated with bands, giving a striped appearance. The
glomeruli showed an increase in matrix and 2 were totally
sclerosed; this was compatible with focal segmental
glomerular sclerosis. No vascular or tubular epithelial lesions
were present. The interstitial changes with associated
tubular changes were compatible with chronic cyclosporin
toxicity. A postmortem biopsy specimen from the black child
who died 2,5 years after cessation of CyA therapy showed
end-stage renal damage. Forty-two glomeruli were present;
30 were sclerosed, while the others showed varying degrees
of mesangial matrix and cellular increase. Two glomeruli
showed pseudotubular formation. These findings supported
the diagnosis of focal segmental glomerular sclerosis. The
basement membrane was normal and the tubules showed
acute tubular necrosis. The interstitium showed a severe
diffuse chronic interstitial nephritis with fibrosis, collections
of foam cells and tubular necrosis. The vessels were
markedly involved, showing hyaline thickening of the walls
with narrowed lumina. These are features of focal glomerular
sclerosis, end-stage kidney disease with superimposed
acute tubular necrosis, and probable cyclosporin toxicity.
No renal biopsy specimen was obtained from the Indian boy
who died 10 months after cessation of CyA therapy.
Changes in Iymphocyte subpopulations
over 24 weeks of treatment
Lymphocyte subpopulations were also studied in this group
of patients and the findings have been published previously.]
There was a tendency for the numbers of T3, T4 and T8
cells and the T41T8 ratio to regress towards the mean of
controls.
Discussion
This pilot study of CyA therapy in 7 black children and 1
Indian child with NS has not provided evidence of any
substantial benefit from this drug, which was associated
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with serious side-effects in at least 1 of the 8 patients.
Difficulties with this study are that the duration of treatment
was too long and the trough levels of CyA were too high and
potentially toxic in the light of current experience. 'o Further,
the incorporation into the study of three different histological
types of NS introduced another variable. Paucity of
information in 1984 regarding 'safe' trough levels in children
influenced therapy and the very serious constraints of
conducting such an assessment in a Third-World situation
narrowed the choice of suitable participants. It is now
known that the adverse renal side-effects of CyA involve
both function and structure of the kidney."
At the completion of a minimum of 24 weeks of CyA
treatment in the 8 children available for evaluation, there was
no significant change in the features of the NS in 6 patients,
and 2 had undergone remission; these 2 children had HBs-
positive membranous nephropathy and in 1 the serum went
on to clear of HBs and HBe. Improvements in the clinical
condition of these 2 patients began before what were at that
time regarded as adequate whole-blood trough levels of
CyA had been achieved; furthermore, in our experience a
third of such patients achieve spontaneous remission, with
time, in the absence of specific therapy. Accordingly, it is
uncertain whether remission in these 2 children was CyA-
induced or part of the natural history of the disease. In
neither of them was any drug toxicity produced.
Three of the 6 children whose clinical status had remained
unchanged after the use of CyA progressed to chronic renal
failure; 2 of these died, both of whom had FGS, a
histological group noted for relentless deterioration. It would
appear, therefore, that CyA intervention did not alter the
expected course in these 2 patients; renal tissue was
unavailable in one, and was suggestive of CyA side-effects
in the other. One of these 3 children (the black child with an
initial diagnosis of MCD but found to have FGS on
subsequent biopsy) had, in addition, developed profound
tubular damage resulting in Fanconi-type rickets; repeat
renal biopsy 13 months after cessation of therapy revealed
features considered by one of two pathologists to be
probable chronic side-effects of CyA. Renal tubular damage
and dysfunction have been documented with CyA
therapy,'2.• but to the best of our information tubular rickets
has not been reported. Low levels of serum calcium and
vitamin D occur with NS,12 but rarely lead to frank rickets. In
NS, partial or complete Fanconi's syndrome does occur, but
is extremely rare and suggests FGS.13 The 3 remaining
children in whom repeat renal biopsies were done at the end
of 24 weeks showed no evidence of acute CyA toxicity.
There are 3 studies on the use of CyA in children with
NS3.4.14 with which it is important to compare the above
results. Cyclosporin in a dosage of 6 - 11 mg/kg/d, with
plasma trough levels of 50 - 150 ng/ml, has been shown by
Niaudet et al. 4 to be effective in steroid-sensitive patients
with NS, and it was suggested that CyA was indicated in
those who had steroid toxicity. However, most patients
appeared to relapse on cessation of CyA; furthermore,
transient renal insufficiency was evident in 2 steroid-
sensitive and 6 steroid-resistant patients. In 5 of these
patients renal insufficiency reversed or improved, but, in 1,
end-stage renal failure developed within 14 months of the
last dose of CyA. This particular case is comparable to our
patient who developed chronic renal failure and rickets.
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Tejani et al. 3 reported success with a relatively short
(8-week) course of CyA 7 mg/kg/d in steroid-resistant or
dependent children with NS classified histologically as FGS,
IgM nephropathy and diffuse mesangial proliferative
nephritis. From this evidence a response to CyA might have
been expected in our 4 FGS patients; none responded or
even improved, 2 sUbsequently died, and 1 developed
chronic renal failure with profound tubular damage. Brodehl
et al." showed that CyA induced remission in steroid-
dependent MCD, but relapses recurred on withdrawal of the
CyA, and 50% of patients with steroid-resistant FGS
responded to CyA.
Sequential studies of patients on CyA have revealed a
decrease in the T4!T8 ratio, mainly due to a reduction in T4
cells." However, CyA also inhibits cytotoxic T lymphocytes.'6
CyA appeared to alter numbers of immunoregulatory cells in
this study, with changes in the T4!T8 ratios from normal. l7
The tentative implications otthis study are that CyA
should be used with great caution at lower dosages and
lower trough levels for the monitoring of the drug. In FGS, in
which prognosis can be poor and newer forms pf treatment
are needed, these early findings indicate that CyA is not
useful and may potentially be harmful.
Relapse of the NS on cessation of CyA therapy is an even
greater disadvantage in the South African black child, for
whom regular follow-up is a major difficulty. The use of a
potentially toxic drug such as CyA for MCD, which has an
excellent long-term prognosis, is difficult to justify.
From current knowledge it is now clear that steroid-
resistant children with NS are more likely to develop CyA-
induced nephrotoxicity,'8 and that the duration of therapy in
this study was far too long,'° thereby increasing this risk.
We thank Sandoz for providing the cyclosporin, Miss R.
Seetal for typing the manuscript, and the Superintendent of
King Edward VIII Hospital for permission to study the
patients. Professor M. Adhikari is in receipt of an MRC
grant.
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The risk of schistosomiasis
in Zimbabwean triathletes
A. K. Jeans, M. P. Schwellnus
A study was carried out to determine the risk of
schistosomiasis in triathletes in Zimbabwe. The
prevalence of schistosomiasis in 30 triathletes (24 males,
6 females) was compared with that in 24 non-triathlete
controls after the 1989/90 triathlon season. All the
subjects found to be infected were then treated with
praziquantel (40 mg/kg). The seasonal incidence of
schistosomiasis in triathletes was then determined in a
prospective study during the 1990/91 season.
Schistosomiasis was diagnosed by urine and stool
.microscopy for ova, blood eosinophil counts and
serological bilharzial fluorescent antibody tests for IgM
and IgG antibodies: There was a significantly (P < 0,05)
higher prevalence of schistosomiasis among the triathietes
(80%) than among the controls (38%). The seasonal
incidence of schistosomiasis was 64%. Exposure of
triathletes to fresh-water dam swimming in Zimbabwe
poses a significant risk for the development of
schistosomiasis.
S Afr Med J 1994; 84: 756-758.
In recent years the sport of triathlon (cycling, swimming and
running) in Zimbabwe has been characterised by an
increasing number of local and overseas competitors who
enter the major standard-distance triathlon events on the
national race calendar. In the 1989/90 season (October-
April) the 1,5 km swim legs of some of the major triathlon
events in Zimbabwe were moved away from chlorinated
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